Tevogen (TVGN) Total Current Liabilities (2021 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Total Current Liabilities came in at $7.3 million in Q1 2026, down 16.64% YoY from $8.7 million in Q1 2025, and up 2.83% on a QoQ basis from $7.1 million in Q4 2025.
Tevogen (TVGN) Total Current Liabilities (2021 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 6 years of Total Current Liabilities data on file, last reported at $7.3 million in Q1 2026.
- Quarterly Total Current Liabilities fell 16.64% year-over-year to $7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 million (down 16.64% YoY) and the FY2025 annual result came in at $7.1 million, down 21.83% from the prior year.
- Total Current Liabilities climbed to $7.3 million in Q1 2026, from $7.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $85.5 million in Q4 2023 to a low of $178999.0 in Q1 2022.
- A 5-year average of $9.8 million and a median of $7.1 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Current Liabilities surged 24291.09% — and 2024, when it tumbled 89.42%.
- Tracing TVGN's Total Current Liabilities over 5 years: stood at $350454.0 in 2022, then surged by 24291.09% to $85.5 million in 2023, then plunged by 89.42% to $9.0 million in 2024, then retreated by 21.83% to $7.1 million in 2025, then increased by 2.83% to $7.3 million in 2026.
- The last three Total Current Liabilities figures came in at $7.3 million (Q1 2026), $7.1 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Tevogen | 25.62 Mn | 25.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.27 Mn |
| Dec 31, 2025 | 7.07 Mn |
| Sep 30, 2025 | 6.74 Mn |
| Jun 30, 2025 | 8.08 Mn |
| Mar 31, 2025 | 8.72 Mn |
| Dec 31, 2024 | 9.04 Mn |
| Sep 30, 2024 | 10.42 Mn |
| Jun 30, 2024 | 10.61 Mn |
| Mar 31, 2024 | 8.94 Mn |
| Dec 31, 2023 | 85.48 Mn |
| Sep 30, 2023 | 1.83 Mn |
| Jun 30, 2023 | 1.52 Mn |
| Mar 31, 2023 | 667,074.00 |
| Dec 31, 2022 | 350,454.00 |
| Sep 30, 2022 | 281,783.00 |
| Jun 30, 2022 | 259,234.00 |
| Mar 31, 2022 | 178,999.00 |
| Dec 31, 2021 | 59,375.00 |